Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL794054 | 0.83 | MAPT (0.42) | GPR119CYP2E1CYP2C8CYP2D6CYP2A6 | |
| SCHEMBL3822143 | 0.80 | CYP2E1 (0.57) | GPR119CYP2E1CYP2C8CYP2D6CYP2A6 | |
| SCHEMBL17377024 | 0.80 | MAPT (0.49) | GPR119KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL1447858 | 0.77 | HTT (0.42) | GPR119CYP2E1CYP2C8CYP2D6CYP2A6 | |
| SCHEMBL3280017 | 0.77 | NCOA3 (0.42) | GPR119CYP2E1CYP2C8CYP2D6CYP2A6 | |
| SCHEMBL3280015 | 0.77 | HTT (0.42) | GPR119CYP2E1CYP2C8CYP2D6CYP2A6 | |
| Hydrochloric Acid SCHEMBL15905458 | 0.75 | HTT (0.41) | GPR119CYP2E1CYP2C8CYP2D6CYP2A6 | |
| SCHEMBL4748186 | 0.75 | ALDH1A1 (0.48) | KDM4EALDH1A1 | |
| SCHEMBL13320901 | 0.74 | MAPT (0.44) | ELANEHTTKDM4EALDH1A1MAPT | |
| SCHEMBL8071332 | 0.74 | AOC1 (0.55) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786177-B2 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7645770-B2 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2010-01-12 | — | — | US | disclosed |
| US-20090186914-A1 | Phenylalanine Enamide Derivatives | UCB PHARMA, S.A. (BE) | 2009-07-23 | — | — | US | disclosed |
| US-7531549-B2 | Phenylalanine enamide derivatives | UCB PHARMA, S.A. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-20090105291-A1 | Phenylalanine Enamide Derivatives | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-7501437-B2 | Phenylalanine enamide derivatives | UCB PHARMA, S.A. (BE) | 2009-03-10 | — | — | US | disclosed |
| CN-101293867-A | Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors | CELLTECH R&D LTD (GB) | 2008-10-29 | — | — | CN | disclosed |
| CN-100400513-C | Phenylalanine enamide derivatives containing cyclobutene groups for use as integrin inhibitors | CELLTECH R&D LTD (GB) | 2008-07-09 | — | — | CN | disclosed |
| EP-1332132-B1 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | UCB PHARMA SA (BE) | 2007-10-10 | — | — | EP | disclosed |
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | UCB PHARMA S.A. (BE) | 2007-07-19 | — | — | US | disclosed |
| CN-1582276-A | Phenylalanine enamide derivatives | CELLTECH R&D LTD (GB) | 2005-02-16 | — | — | CN | disclosed |
| US-6780874-B2 | AUTOIMMUNE DISEASE; ANTIINFLAMMATORY AGENTS; ANTIPROLIFERATIVE AGENT | CELLTECH R & D LIMITED (GB) | 2004-08-24 | — | — | US | disclosed |
| EP-1370531-A1 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | Celltech R & D Limited (GB) | 2003-12-17 | — | — | EP | disclosed |
| US-20030229116-A1 | ENAMINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2003-12-11 | — | — | US | disclosed |
| US-6610700-B2 | Inhibit binding of integrins to their ligands, use in immune or inflammatory disorders; 3-(4-((2,6-Naphthyridinyl)amino)-phenyl)-2-((2-(1-ethylpropyl)-3-oxo-1 -cyclopentenyl) amino)-propionic acid, for example | CELLTECH R & D LIMITED (GB) | 2003-08-26 | — | — | US | disclosed |
| US-6545013-B2 | Of squaric acids; inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells. | CELLTECH R&D LIMITED (GB) | 2003-04-08 | — | — | US | disclosed |
| US-20020169336-A1 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2002-11-14 | — | — | US | disclosed |
| WO-2002068393-A1 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | CELLTECH R & D LIMITED (GB) | 2002-09-06 | — | — | WO | disclosed |
| US-20020115684-A1 | 2, 7-naphthyridine derivatives | CELLTECH R&D, LTD. (GB) | 2002-08-22 | — | — | US | disclosed |
| US-20020037909-A1 | Enamine derivatives | UCB PHARMA S.A. (BE) | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037909-A1 | Enamine derivatives | CCR1, ITGB2, CCR10 | GPR119 735/4885CYP2E1 277/4885CYP2C8 1202/4885 |
| US-20090105291-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, PRLHR | GPR119 519/4885CYP2E1 889/4885CYP2C8 1065/4885 |
| US-20030229116-A1 | ENAMINE DERIVATIVES | ITGB2, CCR1, CCR10 | GPR119 754/4885CYP2E1 306/4885CYP2C8 1339/4885 |
| US-20020169336-A1 | Phenylalanine enamide derivatives | CCR1, AHR, PAH | GPR119 397/4885CYP2E1 654/4885CYP2C8 1083/4885 |
| US-20020115684-A1 | 2, 7-naphthyridine derivatives | VCAM1, ICAM1, SELL | GPR119 677/4885CYP2E1 934/4885CYP2C8 3004/4885 |
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | ITGB2, VCAM1, ITGB1 | GPR119 431/4885CYP2E1 1144/4885CYP2C8 2712/4885 |
| US-20090186914-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, PRLHR | GPR119 519/4885CYP2E1 889/4885CYP2C8 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.